Abcellera Biologics Inc
NASDAQ:ABCL
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.39
5.97
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Abcellera Biologics Inc
Abcellera Biologics Inc
Revenue
Abcellera Biologics Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Revenue
$38m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Revenue
CA$4.5m
|
CAGR 3-Years
29%
|
CAGR 5-Years
173%
|
CAGR 10-Years
54%
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Revenue
CA$353.7k
|
CAGR 3-Years
-5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-22%
|
|
|
Innovotech Inc
XTSX:IOT
|
Revenue
CA$1.2m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
5%
|
|
Abcellera Biologics Inc
Revenue Breakdown
Breakdown by Geography
Abcellera Biologics Inc
|
Total Revenue:
38m
USD
|
|
Canada:
36m
USD
|
|
United States:
2m
USD
|
Breakdown by Segments
Abcellera Biologics Inc
|
Total Revenue:
38m
USD
|
|
Research Fees:
35.6m
USD
|
|
Milestone Payments:
1.5m
USD
|
|
Licensing Revenue:
969k
USD
|
Abcellera Biologics Inc
Glance View
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.
See Also
What is Abcellera Biologics Inc's Revenue?
Revenue
38m
USD
Based on the financial report for Dec 31, 2023, Abcellera Biologics Inc's Revenue amounts to 38m USD.
What is Abcellera Biologics Inc's Revenue growth rate?
Revenue CAGR 5Y
34%
Over the last year, the Revenue growth was -92%. The average annual Revenue growth rates for Abcellera Biologics Inc have been -45% over the past three years , 34% over the past five years .
You don't have any saved screeners yet
